Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma

We compared functional imaging modalities including PET with 6-18F-fluorodopamine (18F-DA) with 123I-metaiodobenzylguanidine (123I-MIBG) and somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO). Methods: We studied 25 men and 28 women (mean age ± SD, 44.2 ± 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: 18F-DA PET, 123I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis. Results: For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for 18F-DA PET, 76.0% for 123I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for 18F-DA PET, 63.4% for 123I-MIBG scintigraphy, and 64.0% for SRS. Conclusion: If available, 18F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than 123I-MIBG scintigraphy or SRS. If 18F-DA PET is not available, 123I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.

[1]  P. Pinto,et al.  Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET , 2007, Journal of Nuclear Medicine.

[2]  J. Carrasquillo,et al.  Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Marzola,et al.  Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study , 2006, Nuclear medicine communications.

[4]  M. Marzola,et al.  A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. , 2006, Endocrine-related cancer.

[5]  J. Carrasquillo,et al.  Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites , 2006, Nuclear medicine communications.

[6]  K. Schmid,et al.  Differential Expression of the Human Somatostatin Receptor Subtypes sst1 to sst5 in Various Adrenal Tumors and Normal Adrenal Gland , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  S. Ezuddin,et al.  MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. , 2005, Clinical nuclear medicine.

[8]  D. Goldstein,et al.  Functional imaging of endocrine tumors: role of positron emission tomography. , 2004, Endocrine reviews.

[9]  F. Telischi,et al.  Octreotide Scintigraphy in the Head and Neck , 2004, The Laryngoscope.

[10]  H. Engler,et al.  Pheochromocytomas: detection with 11C hydroxyephedrine PET. , 2004, Radiology.

[11]  I. Ilias,et al.  Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  S. Schulz,et al.  Immunohistochemical Determination of Somatostatin Receptor Subtypes 1, 2A, 3, 4, and 5 in Various Adrenal Tumors , 2004, Endocrine research.

[13]  P. Herman,et al.  Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Carrasquillo,et al.  Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  E. Krenning,et al.  Octreoscan radioreceptor imaging , 2003, Endocrine.

[16]  J. Schipper,et al.  18F-DOPA positron emission tomography for the detection of glomus tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  H. Neumann,et al.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.

[18]  S. Hasegawa,et al.  Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. , 2001, The European journal of surgery = Acta chirurgica.

[19]  J. Doppman,et al.  A "pheo" lurks: novel approaches for locating occult pheochromocytoma. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  Graeme Eisenhofer,et al.  6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.

[21]  T. Visser,et al.  Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives , 2001, European Journal of Nuclear Medicine.

[22]  W. Linehan,et al.  Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma , 2001, Annals of Internal Medicine.

[23]  R. Reznek,et al.  Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  K. Kanazawa,et al.  Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. , 2000, Clinical nuclear medicine.

[25]  M. Mannelli,et al.  Pheochromocytoma in Italy: a multicentric retrospective study. , 1999, European journal of endocrinology.

[26]  B. Shulkin,et al.  Nuclear medicine imaging of pheochromocytoma and neuroblastoma. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[27]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[28]  W. Linehan,et al.  Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. , 1999, The New England journal of medicine.

[29]  H. Kiyota,et al.  Diagnosis of pheochromocytoma using [123I]‐ compared with [131I]‐metaiodobenzylguanidine scintigraphy , 1999, International journal of urology : official journal of the Japanese Urological Association.

[30]  L. Vlahos,et al.  Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors. , 1997, Anticancer research.

[31]  M. Salvatore,et al.  Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. , 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[32]  M. Rehling,et al.  Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. , 1996, Clinical nuclear medicine.

[33]  B. Shulkin,et al.  The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. , 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[34]  M. Salvatore,et al.  Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. , 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[35]  G. Rubini,et al.  1-131 MIBG Scintigraphy of Neuroectodermal Tumors Comparison Between 1-131 MIBG and ln-111 DTPA-Octreotide , 1995, Clinical nuclear medicine.

[36]  E. Bravo,et al.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.

[37]  K. Langen,et al.  Localization of a pheochromocytoma using I-123 MIBG adrenal scintigraphy. , 1994, Journal of postgraduate medicine.

[38]  T. Thien,et al.  114 Plasma metanephrines in the diagnosis of pheochromocytoma , 1993 .

[39]  T. Visser,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[40]  D. Kuhl,et al.  PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Icrp.  Radiation dose to patients from radiopharmaceuticals , 1988 .

[42]  J. Pool,et al.  Localization of ectopic pheochromocytomas by magnetic resonance imaging. , 1987, The American journal of medicine.

[43]  Paul Kinahan,et al.  Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma , 2006 .

[44]  T. Bley,et al.  Imaging of pheochromocytoma and paraganglioma , 2004, Familial Cancer.

[45]  H. Bonjer,et al.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. , 2001, The Journal of clinical endocrinology and metabolism.

[46]  F. Telischi,et al.  evaluation of head and neck lesions. 111In octreotide scintigraphy in the , 1997 .

[47]  B. Caillou,et al.  Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  J. D. Harrison,et al.  Radiation Dose to Patients from Radiopharmaceuticals , 1988 .

[49]  L. Peyrin,et al.  [Malignant pheochromocytoma]. , 1979, Archives des maladies du coeur et des vaisseaux.